MindMed provides 2024 outlook; GAD Phase 2b showed 7.6-point HAM-A reduction, ADHD trial failed

Definium Therapeutics, Inc.

MM-120 100µg GAD: 7.6 HAM-A reduction vs placebo (p<0.0004, effect size 0.88); 78% response, 50% remission.
ADHD Phase 2a sub-perceptual dose trial failed primary endpoint; no further development for that regimen.
End-of-Phase 2 FDA meeting H1 2024; Phase 3 initiation expected H2 2024 for MM-120 in GAD.
Full 12-week Phase 2b results for MM-120 in GAD expected by Q1 2024 end.
Phase 1 for MM-402 (R(-)-MDMA) in ASD started Q4 2023; UHB MDMA trial topline data H1 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.